Chemo-ablation of Upper-Tract Urothelial Carcinoma

Co-Host: Vitaly Margulis, MD At the conclusion of these activities, participants will be able to: 1. Identify new technologies for the treatment of urothelial carcinoma and analyze the risks and benefits of treatment. 2. Facilitate discussions with patients and caregivers regarding of urothelial carcinoma treatment options. CME Available: https://auau.auanet.org/node/26079 This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma